Latest News for: tnbc

Edit

Updated Efficacy Data of Ivonescimab Combined with Chemotherapy as First-Line Treatment for TNBC Presented at ...

The Sun Chronicle 11 Dec 2025
HONG KONG, Dec. 10, 2025 /PRNewswire/ -- Akeso, Inc.
Edit

Evaluation of the safety and efficacy of ivonescimab in combination with chemotherapy as first-line (1L) treatment for triple-negative breast cancer (TNBC): Updated findings from the open-label, phase II study (Summit Therapeutics Inc)

Public Technologies 11 Dec 2025
). The text version of this document is not available ... Attachments Permalink. Disclaimer.
Edit

Updated Efficacy Data of Ivonescimab Combined with Chemotherapy as First-Line Treatment for TNBC Presented at ESMO IO 2025

PR Newswire 11 Dec 2025
With the follow-up period now extended to 22.1 months, the study further validates the efficacy and safety profile of the ivonescimab regimen in first-line TNBC treatment. As of July 15, 2025, a total of 36 patients with TNBC were enrolled.
Edit

Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+

PR Newswire 10 Dec 2025
First patient from TNBC trial demonstrated 76% tumor volume shrinkage with corresponding reductions in circulating tumor cells (CTC) and clusters ... TNBC Phase 1b Trial ... Across HER2+ and TNBC ex-vivo datasets, a consistent theme emerges.
Edit

SAGA Diagnostics’ Pathlight™ MRD Further Demonstrates Clinical Validity In TNBC Trials Presented at SABCS

Business Wire 09 Dec 2025
MORRISVILLE, N.C.--(BUSINESS WIRE)-- #BreastCancer--SAGA Diagnostics to present data from two trials using Pathlight to evaluate neoadjuvant therapy outcomes in triple-negative breast cancer at SABCS ... .
Edit

Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update ...

Index-Journal 19 Nov 2025
KZIA), an oncology-focused drug development company, today ...
Edit

Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy

PR Newswire 18 Nov 2025
Complete responses in stage IV metastatic TNBC are exceedingly uncommon across many therapeutic classes, including immunotherapy, chemotherapy, and antibody–drug conjugates ... for metastatic TNBC.
Edit

Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regimen (Form 6-K) (Kazia Therapeutics Limited)

Public Technologies 02 Oct 2025
Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regimen ... The patient is a 40+ year old female initially diagnosed with TNBC in April 2023.
Edit

Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regimen

PR Newswire 02 Oct 2025
The patient is a 40+ year old female initially diagnosed with TNBC in April 2023 ... About the ongoing Phase 1b TNBC trial ... with Keytruda® and chemotherapy for advanced breast cancer, including TNBC.
  • 1

Article Search

tools
×
×
×
×